Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
325
Frequently Asked Questions
What is Market Cap of Karyopharm Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Karyopharm Therapeutics Inc market cap is $131.61M.
What is the 52-week high for Karyopharm Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Karyopharm Therapeutics Inc 52 week high is $2.79 as of May 05, 2024.
What is the 52-week low for Karyopharm Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Karyopharm Therapeutics Inc 52 week low is $0.6174 as of May 05, 2024.
What is Karyopharm Therapeutics Inc stock price today?
Karyopharm Therapeutics Inc stock price today is $1.13.
What was Karyopharm Therapeutics Inc stock price yesterday?
Karyopharm Therapeutics Inc stock price yesterday was $1.08.
What is the PE ratio of Karyopharm Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Karyopharm Therapeutics Inc’s P/E ratio is -0.90.
What is the Price-to-Book ratio of Karyopharm Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Karyopharm Therapeutics Inc P/B ratio is -0.9534.
What is Karyopharm Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Karyopharm Therapeutics Inc's EBITDA is -0.65.
What is the 50-day moving average of Karyopharm Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Karyopharm Therapeutics Inc 50-day moving average is $1.30.
How many employess does Karyopharm Therapeutics Inc has?